Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C20H22N2S |
| Molecular Weight | 322.4689 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
c1ccc2c(c1)N(CC3CN4CCC3CC4)c5ccccc5S2
InChI
InChIKey=HOKDBMAJZXIPGC-UHFFFAOYSA-N
InChI=1S/C20H22N2S/c1-3-7-19-17(5-1)22(18-6-2-4-8-20(18)23-19)14-16-13-21-11-9-15(16)10-12-21/h1-8,15-16H,9-14H2
| Molecular Formula | C20H22N2S |
| Molecular Weight | 322.4689 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionCurator's Comment:: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB01071
Curator's Comment:: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB01071
Mequitazine (PRIMALAN®) is a phenothiazine derivative and a histamine H1-receptor antagonist. It competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3943 |
280.0 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | PRIMALAN Approved UseAntihistamine for the treatment of allergic conditions such as hay fever, perennial rhinitis, urticaria, pruritis of allergic origin and allergic reactions associated with insect bites and stings. Launch Date4.71743988E11 |
|||
| Primary | PRIMALAN Approved UseAntihistamine for the treatment of allergic conditions such as hay fever, perennial rhinitis, urticaria, pruritis of allergic origin and allergic reactions associated with insect bites and stings. Launch Date4.71743988E11 |
|||
| Primary | PRIMALAN Approved UseAntihistamine for the treatment of allergic conditions such as hay fever, perennial rhinitis, urticaria, pruritis of allergic origin and allergic reactions associated with insect bites and stings. Launch Date4.71743988E11 |
|||
| Primary | PRIMALAN Approved UseAntihistamine for the treatment of allergic conditions such as hay fever, perennial rhinitis, urticaria, pruritis of allergic origin and allergic reactions associated with insect bites and stings. Launch Date4.71743988E11 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| "In vivo" and "in vitro" evaluation of four antihistamines (astemizole, azatadine, mequitazine, terfenadine). | 1989 Mar-Apr |
|
| The histamine H1-receptor antagonist binding site. A stereoselective pharmacophoric model based upon (semi-)rigid H1-antagonists and including a known interaction site on the receptor. | 1995 Aug 18 |
|
| In vivo and in vitro interaction of the novel selective histamine H1 receptor antagonist mizolastine with H1 receptors in the rodent. | 1995 May |
|
| Efficacy of mequitazine in comparison with placebo assessed by ocular challenge with allergen in allergic conjunctivitis. | 1997 Apr |
|
| Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. | 1998 Feb |
|
| Ketoconazole potentiates terfenadine-induced apoptosis in human Hep G2 cells through inhibition of cytochrome p450 3A4 activity. | 2002 |
Sample Use Guides
The usual dose for adults is one 5 mg tablet to be taken orally twice a day, although in elderly patients (over 65 years) caution should be used.
Route of Administration:
Oral
The affinity of mequitazine for H1 receptors in guinea pigs was compared with that of classical sedative antihistamines ((+)-chlorpheniramine and promethazine). In vitro determinations of Ki values of [3H]mepyramine binding in the brain reveal that mequitazine is 15 to 20 times less potent than (+)-chlorpheniramine and promethazine (Ki value was 280 nM, 12 nM and 17 nM, respectively).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 11:45:42 UTC 2021
by
admin
on
Sat Jun 26 11:45:42 UTC 2021
|
| Record UNII |
Y463242LY2
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QR06AD07
Created by
admin on Sat Jun 26 11:45:42 UTC 2021 , Edited by admin on Sat Jun 26 11:45:42 UTC 2021
|
||
|
WHO-ATC |
R06AD07
Created by
admin on Sat Jun 26 11:45:42 UTC 2021 , Edited by admin on Sat Jun 26 11:45:42 UTC 2021
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C006069
Created by
admin on Sat Jun 26 11:45:42 UTC 2021 , Edited by admin on Sat Jun 26 11:45:42 UTC 2021
|
PRIMARY | |||
|
M7201
Created by
admin on Sat Jun 26 11:45:42 UTC 2021 , Edited by admin on Sat Jun 26 11:45:42 UTC 2021
|
PRIMARY | Merck Index | ||
|
29216-28-2
Created by
admin on Sat Jun 26 11:45:42 UTC 2021 , Edited by admin on Sat Jun 26 11:45:42 UTC 2021
|
PRIMARY | |||
|
29528
Created by
admin on Sat Jun 26 11:45:42 UTC 2021 , Edited by admin on Sat Jun 26 11:45:42 UTC 2021
|
PRIMARY | RxNorm | ||
|
29216-28-2
Created by
admin on Sat Jun 26 11:45:42 UTC 2021 , Edited by admin on Sat Jun 26 11:45:42 UTC 2021
|
PRIMARY | |||
|
Y463242LY2
Created by
admin on Sat Jun 26 11:45:42 UTC 2021 , Edited by admin on Sat Jun 26 11:45:42 UTC 2021
|
PRIMARY | |||
|
C170162
Created by
admin on Sat Jun 26 11:45:42 UTC 2021 , Edited by admin on Sat Jun 26 11:45:42 UTC 2021
|
PRIMARY | |||
|
MEQUITAZINE
Created by
admin on Sat Jun 26 11:45:42 UTC 2021 , Edited by admin on Sat Jun 26 11:45:42 UTC 2021
|
PRIMARY | |||
|
DB01071
Created by
admin on Sat Jun 26 11:45:42 UTC 2021 , Edited by admin on Sat Jun 26 11:45:42 UTC 2021
|
PRIMARY | |||
|
4066
Created by
admin on Sat Jun 26 11:45:42 UTC 2021 , Edited by admin on Sat Jun 26 11:45:42 UTC 2021
|
PRIMARY | |||
|
3672
Created by
admin on Sat Jun 26 11:45:42 UTC 2021 , Edited by admin on Sat Jun 26 11:45:42 UTC 2021
|
PRIMARY | |||
|
CHEMBL1908311
Created by
admin on Sat Jun 26 11:45:42 UTC 2021 , Edited by admin on Sat Jun 26 11:45:42 UTC 2021
|
PRIMARY | |||
|
249-521-7
Created by
admin on Sat Jun 26 11:45:42 UTC 2021 , Edited by admin on Sat Jun 26 11:45:42 UTC 2021
|
PRIMARY | |||
|
1707
Created by
admin on Sat Jun 26 11:45:42 UTC 2021 , Edited by admin on Sat Jun 26 11:45:42 UTC 2021
|
PRIMARY | |||
|
SUB08766MIG
Created by
admin on Sat Jun 26 11:45:42 UTC 2021 , Edited by admin on Sat Jun 26 11:45:42 UTC 2021
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
|
ENANTIOMER -> RACEMATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
